Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036

GILEAD SCIENCES, INC. (GILD)

420
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Sciences : Submits New Drug Application to U.S. FDA for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

04/18/2015 | 11:59pm US/Eastern

Gilead Sciences reported that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/ TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

According to a release from the company, TAF is a novel nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead's Viread (tenofovir disoproxil fumarate, TDF), as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials.

"Gilead has a long history of innovating HIV treatments, and with F/TAF we have the potential to further optimize therapies for HIV patients who face a lifetime of antiretroviral treatment," said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. "With its high antiviral efficacy and favorable safety profile, F/TAF may offer an improved backbone for a new generation of HIV regimens."

Gilead said the filing is its second F/TAF-based NDA submitted to the FDA for review. In November 2014, Gilead filed an NDA for an investigational once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and TAF 10 mg (E/C/F/TAF). Under the Prescription Drug User Fee Act, the FDA has set a target action date of November 5. Additionally, a Marketing Authorization Application in the European Union for E/C/F/ TAF was fully validated on December 23, 2014.

The F/TAF NDA is supported by data from Phase 3 clinical studies evaluating the safety and efficacy of E/C/F/TAF for the treatment of HIV-1 infection among treatment-naive adults, in which the F/TAF- based regimen (administered as E/C/F/TAF) resulted in non-inferior efficacy and improved renal and bone laboratory parameters as compared to F/TDF-based therapy (administered as E/C/F/TDF or Stribild). The NDA is also supported by data from additional Phase 3 studies evaluating the F/TAF-based regimen (administered as E/C/F/ TAF) among treatment-naive adolescents, virologically suppressed adults who switched regimens and adults with mild-to-moderate renal impairment. Lastly, bioequivalence studies demonstrated that the formulation of the fixed-dose combinations of F/TAF achieved the same drug levels in the blood as in E/C/F/TAF.

The recommended dose of F/TAF is 200/25 mg; if it is used in combination with a protease inhibitor that is administered with either ritonavir or cobicistat, the recommended dose is 200/10 mg.

Additional F/TAF-based regimens for HIV treatment are currently in development. In December 2014, Gilead announced the expansion of its existing agreements with Janssen Sciences Ireland UC for the development and commercialization of two new investigational once- daily single tablet regimens containing F/TAF. One combines F/TAF with Janssen's rilpivirine. The other regimen contains F/TAF, cobicistat and Janssen's darunavir.

Gilead plans to submit a regulatory application for F/TAF in the European Union in the second quarter of 2015.

F/TAF-based regimens are investigational products and have not been determined to be safe or efficacious.

Gilead Sciences is a biopharmaceutical company.

More Information:

http://www.gilead.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))

(c) 2015 ProQuest Information and Learning Company; All Rights Reserved., source Trade Publications

React to this article
Latest news on GILEAD SCIENCES, INC.
04/18 GILEAD SCIENCES : Submits New Drug Application to U.S. FDA for Fixed-Dose Combin..
04/16 GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
04/10 GILEAD SCIENCES : Submits New Drug Application to U.S. FDA for Fixed-Dose Combin..
04/07 GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administrat..
04/03DJActavis Seeking FDA Approval to Market Generic Version of Gilead Drug -- Upda..
04/03DJActavis Seeks OK for Generic Version of Gilead Drug
04/03DJActavis Seeking FDA Approval to Market Generic Version of Gilead Drug
04/02 GILEAD SCIENCES : Health Canada warns of side-effects from hepatitis C-heart dru..
04/01 GILEAD SCIENCES : Patent Issued for Processes and Intermediates for Preparing an..
03/31 GILEAD SCIENCES : Japan's Ministry of Health, Labour and Welfare OKs Gilead's So..
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF